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In metastatic colorectal cancer, RAS and BRAF mutations cause resistance to
anti-EGFR therapies, such as cetuximab. Heterogeneity in RAS and BRAF
mutations might explain nonresponse in a subset of patients receiving cetux-
imab. Analyzing mutations in plasma-derived circulating tumor DNA (ctDNA)
could provide a more comprehensive overview of the mutational landscape as
compared to analyses of primary and/or metastatic tumor tissue. Therefore,
this prospective multicenter study followed 34 patients with metastatic colorec-
tal cancer who were tissue-tested as RAS wild-type (exons 2–4) during routine
work-up and received third-line cetuximab monotherapy. BRAF mutation sta-
tus was also tested but did not exclude patients from therapy. At baseline and
upon disease progression, cell-free DNA (cfDNA) was isolated for targeted
next-generation sequencing (NGS). At 8 weeks, we determined that patients
had benefited from treatment. NGS of cfDNA identified three patients with
RAS mutations not detected in tumor tissue during routine work-up. Another
six patients had a BRAF or rare RAS mutation in ctDNA and/or tumor tissue.
Relative to patients without mutations in RAS/BRAF, patients with mutations
at baseline had shorter progression-free survival [1.8 versus 4.9 months
(P < 0.001)] and overall survival [3.1 versus 9.4 months (P = 0.001)]. In
patients with clinical benefit (progressive disease after 8 weeks), ctDNA testing
revealed previously undetected mutations in RAS/BRAF (71%) and EGFR
(47%), which often emerged polyclonally. Our results indicate that baseline
NGS of ctDNA can identify additional RAS mutation carriers, which could
improve patient selection for anti-EGFR therapies. Acquired resistance, in
patients with initial treatment benefit, is mainly explained by polyclonal emer-
gence of RAS, BRAF, and EGFRmutations in ctDNA.
Abbreviations
cfDNA, cell-free DNA; CPCT, Center for Personalized Cancer Treatment; ctDNA, circulating tumor DNA; dPCR, digital polymerase chain
reaction; EGFR, epidermal growth factor receptor; MAF, mutant allele frequency; MATV, metabolically active tumor volume; mCRC,
metastatic colorectal cancer; MoAbs, monoclonal antibodies; NGS, next-generation sequencing; OS, overall survival; PD, progressive
disease; PFS, progression-free survival; RT, room temperature.
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1. Introduction
Patients with metastatic colorectal cancer (mCRC),
harboring RAS mutations, do not benefit from anti-
epidermal growth factor receptor (EGFR) monoclonal
antibodies (MoAbs) such as cetuximab and panitu-
mumab (Sorich et al., 2015). Despite patient selection
for anti-EGFR MoAbs based on RAS mutations in
the tumor, only 40–45% of patients with wild-type
mCRC have clinical benefits resulting in partial
response in 8–13% and stable disease in 32% of
patients (van Helden et al., 2017; Karapetis et al.,
2008; Lievre et al., 2008; Van Cutsem et al., 2015).
Alternative biomarkers to predict treatment benefit are
under investigation, including imaging of tumor
uptake of cetuximab and early response evaluation
with [18F]FDG PET, but have not led to clinical
implementation so far (van Helden et al., 2016;
Menke-van der Houven van Oordt et al., 2015). In
addition to RAS mutations, recent meta-analyses
demonstrated that BRAF-mutated mCRC – which
occurs in 8–10% of patients with RAS wild-type
mCRC – also fails to respond to anti-EGFR MoAbs
(Pietrantonio et al., 2015; Rowland et al., 2015). Con-
sequently, patients with somatic BRAF p.V600E muta-
tions are currently excluded from these therapies in
clinical practice as well as in prospective clinical trials.
A potential explanation for the lack of response in
patients with RAS and BRAF wild-type tumors is the
presence of intralesional and interlesional differences
in mutational status. Although high concordance rates
have been described in some studies (Vermaat et al.,
2012), others do report heterogeneity in RAS and
BRAF mutations ranging from 5% to 32% between
the primary tumor and metastatic sites (Artale et al.,
2008; He et al., 2016; Italiano et al., 2010; Kim et al.,
2012; Vermaat et al., 2012). Tumor heterogeneity
could result in missed RAS- and BRAF-mutated sub-
clones, present under the detection limit of the assay
or not present in the evaluated part of the tumors. In
particular, the potential difference between primary
tumor and metastatic site is of high relevance since in
daily clinical practice primary tumor tissue is fre-
quently being used to assess the mutational status of
an individual’s tumor, leaving mutations in metastatic
cells undetected. This may result in nonresponse when
a patient is treated in the metastatic setting.
Consequently, assessment of the mutational status
of metastatic tissue prior to treatment with anti-EGFR
MoAbs is important. Although a biopsy from a meta-
static lesion can be taken, this is a cumbersome proce-
dure for patients and repetitive sampling is frequently
not feasible. An alternative approach to identify the
complexity and heterogeneity of all metastatic lesions
in a minimally invasive manner is the analysis of
plasma-derived circulating tumor DNA (ctDNA) in
cell-free DNA (cfDNA), which consists of both
healthy and tumor-derived DNA. ctDNA comprises of
short DNA fragments derived from tumor cells and
theoretically represents the whole mutational landscape
of all metastatic sites. Consequently, ctDNA might
give a more accurate representation of the entire muta-
tional profile than a single tumor tissue biopsy.
In untreated patients who started with anti-EGFR
blockade in combination with chemotherapy, it has
been shown that oncogenic mutations as KRAS and
BRAF can be detected in ctDNA (Misale et al., 2012).
In addition, it has been described that mutations can
appear in the circulation after acquired resistance in
patients with initially wild-type disease (Diaz et al.,
2012; Thierry et al., 2014). However, most studies have
described the mutational status in ctDNA by analyzing
a limited number of genes and in patients treated with
combination therapies of a chemotherapy backbone
combined with cetuximab (Spindler et al., 2014;
Thierry et al., 2017; Van Emburgh et al., 2016), which
makes the interpretation of results with respect to anti-
EGFR MoAbs alone difficult.
In this prospective multicenter study, we report the
mutational analyses of ctDNA in a unique cohort of
34 tissue-tested RAS wild-type [codon 12, 13 (exon 2);
59, 61 (exon 3); 117, 146 (exon 4)] mCRC patients
treated with third-line cetuximab monotherapy. Blood
samples were collected prior to cetuximab therapy,
during therapy and at disease progression. Mutations
in ctDNA were measured by a large panel of 14 genes
(236 hotspots), including KRAS, NRAS, EGFR, and
PIK3CA, using a targeted next-generation sequencing
(NGS) approach with molecular barcoding. This
approach allowed us to evaluate genetic profiles under
the sole effect of cetuximab therapy. The aim of this
study was to assess whether ctDNA could further
improve patient selection for anti-EGFR MoAb ther-
apy. In addition, we aimed to gain more insight into
the underlying mechanisms for acquired resistance to
anti-EGFR MoAb monotherapy.
2. Materials and methods
2.1. Study design and patients
The IMPACT-CRC is a prospective phase I–II multi-
center interventional study (registered with ClinicalTri-
als.gov, number NCT02117466) to evaluate the
predictive value of [89Zr]cetuximab PET scans for
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cetuximab treatment response. As part of this study,
plasma for cfDNA analyses was collected at baseline,
after 2 weeks of treatment and at disease progression.
All patients received cetuximab monotherapy as third-
line palliative systemic treatment. All 34 patients
started with 500 mgm2 every other week. Based on
the [89Zr]cetuximab PET/CT, eight patients received a
higher dose cetuximab (750–1250 mgm2), whereas 26
patients continued with 500 mgm2 (E.J. van Helden,
unpublished data). Patients were included in Amster-
dam UMC, Vrije Universiteit Amsterdam, University
Medical Center Groningen, and Radboud University
Medical Center. The study was performed in accor-
dance with the Declaration of Helsinki and approved
by the Medical Research Ethics Committee of the
Amsterdam UMC, Vrije Universiteit Amsterdam. All
patients gave written informed consent prior to study
procedures.
Patients were eligible for inclusion if they had unre-
sectable RAS wild-type metastatic colorectal cancer,
had been treated with or had contra-indications for
standard chemotherapy (fluoropyrimidine, irinotecan,
and oxaliplatin), and were naive for anti-EGFR
MoAbs. In all patients, mutational analysis was per-
formed as part of routine clinical work-up on either
primary or metastatic tumor tissue and had to be RAS
wild-type. RAS wild-type was defined as wild-type in
codons 12, 13 (exon 2); 59, 61 (exon 3); and 117, 146
(exon 4) of KRAS and NRAS. Patients with BRAF
p.V600E mutations were allowed per protocol to par-
ticipate, since only recently became clear that these
patients do also not respond to anti-EGFR MoAbs
(Pietrantonio et al., 2015; Rowland et al., 2015).
Clinical outcome was defined as no clinical benefit
for patients having progressive disease (PD) at 8 weeks
and as clinical benefit for patients with stable disease
or partial response according to RECISTv1.1 at
8 weeks (Eisenhauer et al., 2009). Additionally, pro-
gression-free survival (PFS) and overall survival (OS)
were evaluated, defined as the period between the first
treatment cycle until PD or death, respectively.
Patients that were still on treatment and/or alive at the
last follow-up date (December 1, 2017) were censored.
2.2. Plasma sample collection and handling
Prior to the first cetuximab cycle (baseline), after
2 weeks of treatment and at PD 18 mL of blood was
drawn in Vacutainer EDTA tubes (BD, Franklin
Lakes, NJ, USA). Plasma was isolated within 1 h after
blood collection performing two sequential centrifuga-
tion steps: 820 g of 10 min at room temperature (RT)
with brakes off, and 20 000 g for 10 min at RT. After
centrifugation, plasma was snap-frozen and stored at
80 °C until further handling.
2.3. Tumor tissue handling
According to standard of care, before start with cetux-
imab therapy, formalin-fixed paraffin-embedded mate-
rial of the primary tumor and/or metastasis was tested
for RAS (exon 2–4) and BRAF (exon 15) if the tumor
percentage was ≥ 20% on hematoxylin eosin immuno-
histochemistry staining. For all patients included in the
Amsterdam UMC, Vrije Universiteit Amsterdam, a
TruSeq Amplicon Cancer Panel (TSACP; Illumina Inc,
San Diego, CA, USA) was used as described previously
(Sie et al., 2014). In case, tumor tissue was of insuffi-
cient quality for TSACP-MiSeq-NGS, and a high-reso-
lution melting technology-based approach followed by
direct sequencing to determine RAS and BRAF muta-
tions was performed (Heideman et al., 2012; Kramer
et al., 2009). For all patients included in University
Medical Center Groningen and Radboud University
Medical Center, multiplex PCR and PGM/Ion Torrent
(Life Technologies, Carlsbad, CA, USA) sequence anal-
yses were used as described previously (Boleij et al.,
2015). Multicenter comparison of mutation testing for
RAS and BRAF previously demonstrated an excellent
reproducibility between these Dutch centers (Boleij
et al., 2015).
In addition to routine work-up, some patients
underwent an additional biopsy prior to cetuximab
therapy, which was analyzed via the Center for Per-
sonalized Cancer Treatment (CPCT; NCT01855477).
This Dutch consortium offers next-generation whole-
genome sequencing of snap-frozen tumor material for
the discovery of tumor mutations. To identify true
somatic mutations, germline DNA collected from
whole blood was sequenced in the same fashion as ref-
erence to tumor tissue (Bijlsma et al., 2016). The
sequencing data of this CPCT biopsy came available
after start of cetuximab therapy and did not influence
clinical decision making.
2.4. cfDNA isolation and quantification
For cfDNA isolation, plasma samples were thawed
and 4 mL of plasma was used. cfDNA isolation was
performed for all 34 patients at baseline and 27
patients at disease progression. Additionally, for nine
patients with clinical benefit, cfDNA was isolated from
plasma collected after 2 weeks of treatment. cfDNA
was isolated and eluted in 60 lL buffer using the
QiaSymphony Circulating DNA kit (Qiagen, Venlo,
the Netherlands) as per manufacturer’s instructions
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and stored at 20 °C. CfDNA concentrations were
quantified using the Quant-iT dsDNA high-sensitivity
assay (Invitrogen, Life Technologies, Carlsbad, CA,
USA) according to the manufacturer’s instructions,
and the Qubit fluorometer (Invitrogen) was used as
read out.
2.5. Targeted NGS and digital PCR
A targeted NGS approach with molecular barcoding
using OncomineTM Colon cfDNA Assay (Thermo
Fisher Scientific, Waltham, MA, USA) was applied for
low limit (down to 0.1%) somatic variant detection
according to the manufacturer’s instructions. This
assay consists of 14 colorectal cancer-specific genes
covering 236 hotspots and indels in 49 amplicons,
including AKT1, APC, BRAF, CTNNB1, EGFR,
FBXW7, GNAS, HER2, KRAS, MAP2K1, NRAS,
PIK3CA, SMAD4, and TP53. CfDNA samples were
thawed at RT and a maximum volume input of 13 lL
of the cfDNA eluate was used, unless the amount of
cfDNA in this volume exceeded an input of 20 ng
cfDNA, and then, 20 ng cfDNA was used. This
amount was used to standardize cfDNA input for tar-
geted NGS between patients and allowed us to achieve
a limit of detection of 0.1% (1 mutant copy in a back-
ground of 1000 wild-type copies). Samples with
cfDNA concentrations < 15 nglL1 [33/69 (48%)
samples] were concentrated using the EppendorfTM,
VacufugeTM Concentrator (Fisher Scientific). Baseline
and PD samples originating from the same patient
were sequenced within the same run. Analyses were
done as previously reported, using Ion S5 XL sequenc-
ing system and 540 chips, and evaluated with a stan-
dard variant calling pipeline (Jansen et al., 2016).
First, raw Ion S5 sequencing results with the Onco-
mine cfDNA assays were loaded into the TorrentSuite
variant caller 5.6. Applying additional filtering, hot-
spot variants were called when at least 1000 unique
molecules for that particular position were sequenced
to achieve sufficient coverage for a limit of detection
of 0.1% and if the mutant sequence was covered in
three unique molecules and 10 reads (i.e., three reads
per unique molecule).
Cell-free DNA samples from two patients who har-
bored a BRAF p.V600E mutation in their tumor tissue
and of whom the cfDNA analyses were negative
according to targeted NGS (one sample failed during
NGS, the other one tested wild-type) were additionally
tested for this mutation using a validated digital poly-
merase chain reaction (dPCR) assay (TaqMan SNP
genotyping assays; Thermo Fisher Scientific), as
described previously (van Dessel et al., 2017).
2.6. Tumor load
To compare the total measured cfDNA and ctDNA
(mutant copiesmL1 plasma) with the tumor burden
in a patient, we evaluated tumor load on CT and [18F]
FDG PET/CT scan. On the baseline diagnostic CT
scan, the total number of metastases was evaluated per
patient. Additionally, the sum of diameters of all
tumor lesions was calculated.
Baseline [18F]FDG PET scan was performed within
2 weeks before the first treatment with cetuximab. The
PET scans were created according to EANM guideli-
nes (Boellaard et al., 2010). Briefly, patients fasted 6 h
before tracer injection (target serum glucose
≤ 7 mmolL1). Mid-femur-skull vertex PET-CT was
performed 60 min (5 min) after injection of [18F]
FDG (3–4 MBqkg1) and combined with low-dose
CT (120 kVp, 50 mAs). PET data were normalized
and corrected for scatter and randoms, attenuation,
and decay. Tumor load on [18F]FDG PET scan is
expressed as metabolically active tumor volume
(MATV), which was calculated using a threshold of
50% of peak standard uptake value to define tumor
volume.
2.7. Statistical methods
All statistical analyses were performed using IBM SPSS
version 24 (IBM Corp, Armonk, NY, USA). A P-
value below 0.05 was used as cutoff for significance.
To compare the presence of a mutation with treatment
benefit, a Fisher’s exact test was used. For survival
analysis, patients without progression and patients that
are still alive on December 1, 2017 were censored. Uni-
variate analysis was done using Kaplan–Meier curves
and Log Rank tests. With univariate and multivariate
Cox regression, hazard ratios (HRs) were calculated
(enter method). To correlate the concentration of ng
cfDNA per mL plasma with the total volume of tumor
load, a Spearman’s q was used.
3. Results
3.1. Patients, plasma, and tumor tissue
characteristics
In total, 34 patients were included from May 2014
until December 2016, and patient characteristics are
described in Table 1. At the time of analyses (Decem-
ber 2017), all patients had progressed and 29 (85.3%)
had died. Of all patients, 13 (38%) did not have treat-
ment benefit. The median PFS of the whole cohort
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was 4.0 months (95% CI 2.7–5.2), and median OS was
9.0 months (95% CI 6.0–12.1).
3.2. Plasma isolation and raw analysis of
samples
The median cfNDA concentration at baseline was
49.4 ngmL1 plasma (range 5.5–784 ngmL1
plasma), and at PD 30.8 ngmL1 (range 4.91–
228 ngmL1 plasma). A median of 20 ng (range 11.5–
33.6 ng) was sequenced on the Ion S5 platform
(Table S1). Variants were called based on our defini-
tion of a true positive (molecular coverage of ≥ 1000
and ≥ 10 mutant reads, and ≥ 3 mutated unique mole-
cules). Five hotspots variants, which had a molecular
coverage < 1000, were also considered true positives as
these variants were detected in another sample col-
lected at a different time point as well or if the hotspot
was also detected in tumor tissue. The median molecu-
lar coverage of all amplicons was 2851 (range 0–
20 000), and the median molecular coverage of
mutated hotpots was 3436 (range 71–9641). In total,
three samples failed during the sequencing process and
were omitted from further analyses (Table S2). In sum-
mary, successful sequencing results were obtained from
33 of 34 baseline samples, from 7 of 9 2-week samples,
and all 26 samples at progression (Fig. 1).
3.3. RAS and BRAF mutations in tissue and
ctDNA at baseline
3.3.1. Tissue versus ctDNA
Sequencing results of baseline ctDNA obtained prior
to start of cetuximab therapy were compared to the
mutational status found in routinely tested tumor tis-
sue (Table 2). In patients with treatment benefit
(n = 21), no mutations in KRAS, NRAS, and BRAF
were detected in tumor tissue. In ctDNA, however, a
polyclonal mutation in codons 12 and 61 of KRAS
was found in one patient (no. 23).
In patients without treatment benefit (n = 13), four
BRAF p.V600E mutations and one rare KRAS
p.G60D mutation were detected in tumor tissue. Three
of four BRAF p.V600E mutations were also detected
in baseline ctDNA. In one patient (no. 26), sequencing
of baseline ctDNA failed, but BRAF p.V600E status
was assessed by a dPCR confirming the presence of
the BRAF mutation at a mutant allele frequency
Table 1. Baseline patient characteristics. SD, stable disease; PR, partial response
Characteristics Clinical benefit (%) No clinical benefit (%) Total (%)
No. of patients 21 (62) 13 (38) 34 (100)
Median age (range) 64 (50–82) 64 (55–78) 64 (50–82)
Male gender 17 (81) 8 (62) 25 (73.5)
WHO performance status
0 6 (28.6) 3 (23.1) 9 (26.5)
1 14 (66.7) 8 (61.5) 22 (64.7)
2 1 (4.8) 2 (15.4) 3 (8.8)
Primary tumor
Right-sided 1 (4.8) 8 (61.5) 9 (26.5)
Left-sided 20 (95.2) 5 (38.5) 25 (73.5)
Previous treatments
Fluoropyrimidine 21 (100) 13 (100) 34 (100)
Oxaliplatin 21 (100) 13 (100) 34 (100)
Irinotecan 18 (85.7) 13 (100) 31 (91.4)
Bevacizumab 15 (71.4) 8 (61.5) 23 (67.6)
Sunitinib 1 (4.8) 0 1 (2.9)
RECIST evaluation after 8 weeks
PD 0 13 (100) 13 (38.2)
SD 18 (85.7) 0 18 (52.9)
PR 3 (14.3) 0 3 (8.8)
cfDNA
Median cfDNA concentration in ngmL1 plasma (range) 46.5 (6.6–111) 54 (5.5–174) 49.4 (5.5–174)
KRAS/BRAF mutations 1 (4.8) 7 (53.8) 8 (23.5)
Median MATV on [18F] FDG PET (range) 148 (14–1189) 156 (40–805) 152 (14–1189)
PD at time of analysis 21 (100) 13 (100) 34 (100)
Deceased at time of analysis 16 (76.2) 13 (100) 29 (85.3)
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(MAF) of 6.6%. In another patient (no. 14), the
BRAF mutation was not detected in ctDNA by both
sequencing and dPCR. No additional BRAF mutations
over tumor tissue testing were identified in baseline
ctDNA. The KRAS p.G60D mutation was confirmed
in ctDNA, and two additional KRAS mutations were
detected in ctDNA of patients 4 and 19, which were
not detected in tumor tissue.
3.3.2. Additional tissue analysis
For eight patients, mutational analyses were performed
on two tumor tissue samples obtained prior to start of
treatment (Table S3). Additional sequencing results
came available after start of treatment and therefore
did not influence clinical decision making.
In two patients, a KRAS mutation was found after
an initially RAS wild-type test. Both KRAS mutations
were rare and not known as resistance-inducing muta-
tions, that is, codon 89 (KRAS p.S89P) and codon 60
(KRAS p.G60D). The first mutation was not covered
by the initial RAS analysis; the latter was covered by
the initial sequencing panel, but was not detected in
the initial sample.
3.3.3. RAS/BRAF mutations in ctDNA and tumor
tissue are predictive for treatment response
Patients with any RAS/BRAF mutations in either
tumor tissue or ctDNA had less treatment benefit
than patients who had a negative test result. Eight of
13 (61.5%) patients without clinical benefit had a
Fig. 1. Comparison of mutational status as determined by ctDNA analyses at baseline and PD in patients with and without clinical benefit.
The number behind the ‘X’ indicates the number of hotspot mutations within a gene.
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RAS/BRAF mutation versus one out of 21 (4.8%)
patients with clinical benefit (P = 0.001). PFS was
shorter for patients with RAS/BRAF mutations, with
a median PFS of 1.8 months versus 4.9 months in
wild-type patients (P < 0.001, HR 4.3; 95% CI 1.8–
10.0, Fig. 2A). In multivariate analysis, correcting for
WHO performance status (0 versus 1–2) and left ver-
sus right-sidedness, any RAS or BRAF mutation
remained correlated with PFS (P = 0.004, HR 4.3;
95% CI 1.6–11.6). In line with PFS, OS was shorter
in patients with RAS-/BRAF-mutated disease, with a
median of 3.1 versus 9.4 months (P = 0.001, HR 3.9;
95% CI 1.6–9.3, Fig. 2B). Also, with multivariate
analysis, corrected for sidedness and WHO perfor-
mance status, any RAS/BRAF mutation remained
correlated with OS (P = 0.007, HR 5.8; 95% CI 1.6–
20.7).
3.4. Comparison of mutations in ctDNA:
baseline, 2 weeks on treatment and at
progressive disease
3.4.1. ctDNA mutations at baseline versus 2 weeks
For nine patients with clinical benefit, plasma obtained
after 2 weeks of treatment was available for cfDNA
analyses. cfDNA concentrations decreased from a
median of 44.7 ngmL1 plasma (range 13.3–
784 ngmL1 plasma) at baseline to 18.9 ngmL1
plasma (range 7.4–41.7 ngmL1 plasma) after 2 weeks
of cetuximab treatment (P = 0.008), Fig. S1. Paired
sequencing results showed that the MAF of dominant
tumor clones present at baseline decreased after
2 weeks of treatment, suggesting a reduction in
Table 2. Baseline mutations in genes: BRAF, KRAS, NRAS. Mutations detected in tumor tissue during routine work-up and in cfDNA prior
to start of cetuximab monotherapy. Mutations detected in tumor tissue and ctDNA are expressed in MAF
Genes
Nonresponders (n = 13) Responders (n = 21)
Patient Tissue (MAF%) cfDNA (MAF%) Patient Tissue (MAF%) cfDNA (MAF%)
BRAF 9 p.V600E (13) p.V600E (1.97) – –
14 p.V600E (29) –
26 p.V600E (34) p.V600E (6.6)a
29 p.V600E (44) p.V600E (46.49)
KRAS 4 – p.G12A (1.34) 23 – p.Q61H (0.38)
19 – p.Q61H (0.06) 23 – p.G12A (0.15)
24 p.G60D (43) p.G60D (25.97)b
33 p.S89P (44)c –
NRAS – – – –
aNGS failed, BRAF p.V600E was detected by dPCR. bThis patient received cetuximab despite having a KRAS mutation, as mutations in
codon 60 were not an exclusion criteria. cKRAS mutation detected by WGS, and this test result came available after treatment initiation.
This hotspot is not covered by the OncomineTM Colon cfDNA Assay.
Fig. 2. Progression-free survival (A) and OS (B) for patients with RAS and/or BRAF mutations (mutant) versus patients without RAS/BRAF
mutations (wild-type) in tissue and ctDNA.
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ctDNA load (Fig. 3). Detailed information on posi-
tions of mutations, MAF, and number of mutant
molecules per mL plasma is available in Table S4.
3.4.2. ctDNA mutations at baseline versus at
progressive disease
To explore mechanisms of resistance, we compared the
mutational signature at baseline and at disease pro-
gression. Paired cfDNA sequencing results were avail-
able for 17 patients with clinical benefit and eight
patients without clinical benefit.
In 17 patients with initial clinical benefit, an evident
increase in mutations in well-known resistance-induc-
ing genes as KRAS, NRAS, and BRAF was observed
at the time of progression [median sampling after
25 weeks (range 16–94 weeks)] (Fig. 1). Twelve
patients (71%) had mutations in KRAS (n = 10) either
or not combined with a mutation in NRAS (n = 8)
and/or BRAF (n = 3) at disease progression. The total
number of mutations in KRAS increased from 2 at
baseline to 34 at PD, for NRAS from 0 to 19, and for
BRAF from 0 to 3, respectively. Polyclonal KRAS
mutations were present in one patient at baseline and
in five patients at PD. Polyclonal mutations in NRAS
were present in five patients at PD. For example,
patient 23, who already harbored two KRAS muta-
tions next to a dominant mutation in TP53 at baseline
(21%), showed a marked decrease in the dominant
TP53 mutation after 2 weeks (2%) of treatment and
gained 4 KRAS and 2 NRAS mutations next to a clear
increase in the TP53 mutation (15%) at PD (Fig. S2).
In addition to the already established resistance-in-
ducing genes, the progression samples of patients with
initial response to anti-EGFR MoAbs were also
enriched for EGFR mutations. Mutations in EGFR
were detected in 8/17 (47%) patients at disease pro-
gression, which were not present at baseline, neither in
ctDNA nor in tumor tissue. In 6/8 of patients with an
EGFR mutation, polyclonal mutations occurred. These
EGFR mutations were located in codons 464, 465, and
492, and code for the epitope binding site of cetux-
imab (Sickmier et al., 2016). In addition, the number
of patients harboring MAP2K1 mutations increased
from four at baseline to eight at progression. Taken
together, at disease progression 15/17 patients (88%)
had a mutation related to anti-EGFR MoAbs resis-
tance (12 patients with RAS mutations, two patients
with only MAP2K1 mutations, and one patient with
only an EGFR mutation). Mutated genes and the num-
ber of unique mutations per gene at baseline and PD
are depicted in Fig. 4A.
In patients without clinical benefit, baseline, and PD
(median sampling after 8 weeks, range 3–10 weeks),
ctDNA mutation analyses demonstrated only a few
differences (Fig. 1). Only one patient without baseline
mutations in ctDNA nor tumor tissue gained muta-
tions in KRAS, NRAS, and BRAF at progression in
ctDNA. Patients 4, 19, and 24 gained all one addi-
tional mutation at progression: KRAS, NRAS, and
EGFR mutations, respectively (Fig. 4B).
3.4.3. Baseline ctDNA mutations: clinical benefit versus
no clinical benefit
Baseline ctDNA of patients without clinical benefit
was compared to baseline ctDNA of patients with ini-
tial clinical benefit to define whether there were
Fig. 3. Paired baseline, 2-week, and PD
ctDNA-sequencing results of patients with
clinical benefit. Mutations were grouped
per gene, and if patients harbored
polyclonal mutations, the clones were
numbered. For example, in patient 18 two
TP53 mutations were detected at
baseline, clones 1 and 2, which both
decreased in MAF at 2 weeks.
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differences in affected genes beyond KRAS, NRAS,
and BRAF mutations. APC, TP53, MAP2K1,
SMAD4, and PIK3CA mutations were present in base-
line ctDNA samples of both patient groups. Mutations
in CTNNB1 were only present in baseline samples of
two patients without treatment benefit. However, both
CTNNB1 mutations were present together with a
KRAS mutation. CTNNB1 is associated with constitu-
tive RAF/MEK/ERK pathway activation (Malapelle
et al., 2016). An overview of all mutations, in tissue
and ctDNA from all time points, is shown in
Table S4.
3.5. Left- versus right-sided mCRC
Based on tissue-tested mutation analyses, six out of
nine patients with right-sided mCRC had a RAS or
BRAF mutation. Incorporating the ctDNA mutation
analyses, eight out of nine patients with right-sided
mCRC had a RAS or BRAF mutation (P < 0.001).
The one patient with right-sided mCRC without any
RAS or BRAF mutation experienced treatment benefit,
with disease control of almost 14 months and a cen-
sored OS of 23 months. Only one patient (1/25, 4%)
with left-sided mCRC had a polyclonal KRAS muta-
tion in ctDNA analysis and was free of progression
for 6.2 months and died 8.7 months after start of
cetuximab therapy.
3.6. Tumor load versus cfDNA concentration
The sum of diameters of all metastases per patient did
correlate to baseline cfDNA concentration (P = 0.033),
and also, the number of metastases (median 5.5 lesions,
range 1–15) did correlate with cfDNA concentration
(P = 0.037). Moreover, the MATV on [18F]-FDG PET
highly correlated with baseline concentration cfDNA
(ng cfDNAmL1 plasma) (Spearman’s q 0.67,
P < 0.001; Fig. S3A). In addition, the total number of
hotspot mutant molecules per mL plasma as a surrogate
for mutational load also correlated with MATV on [18F]
FDG PET (Spearman’s q 0.50, P = 0.003) (Fig. S3B).
4. Discussion
The results of the current study indicate that a subset
of patients with RAS wild-type tumors who have no
clinical benefit on cetuximab monotherapy do have
KRAS mutations in ctDNA. Our analysis of patients’
baseline ctDNA revealed three additional patients who
had KRAS mutations (KRAS p.G12A, p.G61H, and a
combination of the two) that had not been detected in
tumor tissue. These discordant findings between tumor
tissue and ctDNA are in line with previous reports
that have demonstrated that mutations can be hetero-
geneous within primary tumor lesions, between syn-
chronous lesions, and between metastases (Jeantet
et al., 2016; Kosmidou et al., 2014; de Macedo et al.,
2015; Normanno et al., 2015; Oltedal et al., 2011).
Apart from such tumor heterogeneity, the sensitivity
of sequencing assays used in tumor tissue testing could
also have led to false-negative results since most of the
clinically used assays have a limit of detection of MAF
> 5% (Shackelford et al., 2012). This hypothesis has
recently been supported by Khan et al. (2018) who
showed that RAS mutations in ctDNA could be
Fig. 4. Paired baseline and PD ctDNA mutational analyses in patients with initial clinical benefit (A) and patients without clinical benefit (B).
Mutations are depicted per gene, each gene having a separate color. Higher bars indicate polyclonal mutations. For example, patient 2
gained seven different KRAS hotspot mutations at disease progression. Patient 20 with clinical benefit and patient 30 without clinical benefit
were not included in the graph because of the absence of mutations at baseline as well as PD.
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confirmed in tumor tissue at low frequencies by using
deep sequencing. The authors found that the MAFs of
mutations detected in tumor tissue were indeed below
the limit of detection of clinically used techniques.
Furthermore, KRAS mutations detected in ctDNA at
baseline were also detected at disease progression with
higher MAFs, endorsing that KRAS is truly mutated
in these cetuximab-naive patients.
While most patients had known resistance-inducing
mutations, one patient harbored a rare KRAS p.G60D
mutation in both tissue and ctDNA. Since this muta-
tion was not in one of the codons known to be resis-
tance-inducing – and there has been anecdotal
evidence of a patient with a p.G60D mutation having
a partial response to cetuximab – this patient was
allowed to participate in the study, but did not benefit
from therapy (Molinari et al., 2011).
As this study included only those patients who had
KRAS and NRAS wild-type disease based on tumor
tissue testing, a comparison of the mutational status
in tissue versus ctDNA was not plausible for these
genes. Since we included patients with BRAF muta-
tions, a comparison of tissue versus ctDNA was pos-
sible in our cohort. We detected BRAF p.V600E
mutations in ctDNA of three patients, in two patients
by sequencing and in one by dPCR, and these BRAF
mutations were also present in tumor tissue. One
BRAF p.V600E mutation was present in tumor tissue
of a fourth patient but was not detected in ctDNA
with targeted NGS nor with an orthogonal technique
as dPCR. We suggest three possible reasons for this.
First, the molecular coverage of BRAF in the NGS
experiment for this patient (patient 14) was 709 mole-
cules. This is far lower than the median molecular
coverage of BRAF of 2191 molecules that we mea-
sured in 67 samples, which might explain why this
variant was not detected. A second possible explana-
tion is that following surgical removal of the primary
tumor that provided tissue for the test, subsequent
metastases originated from a different clone that did
not carry the BRAF mutation. Third, the cfDNA
concentration of this patient was low, only
21.9 ng cfDNAmL1 plasma, which is much lower
than the median baseline cfDNA concentration in
our cohort (49.4 ngmL1 plasma). Since baseline
cfDNA concentration was correlated with tumor
load, low cfDNA concentrations could hypothetically
lead to false-negative results due to the fact the
amount of tumor DNA carrying the mutation present
in the circulation is simply too low. Nevertheless, for
three out of four patients with the mutation in tumor
tissue, the BRAF mutation was also detected in
ctDNA. Although caution is warranted given the
small number of patients, a detection rate of 75% is
in line with that found in a previous study in non-
small-cell lung cancer patients: This study compared
the detection of the EGFR p.T790M mutation in
ctDNA with that in tumor and reported a sensitivity
of 70% (Oxnard et al., 2016).
While almost all patients with additional KRAS or
BRAF mutations were resistant to therapy, we also
had one patient with clinical benefit who nevertheless
had a polyclonal KRAS mutation (p.G61H and
p.G12A) in ctDNA, for which we suggest three
potential explanations. First, this patient received a
cetuximab dose escalation from 500 to 1250 mgm2,
dosed every other week, based on the results of the
[89Zr]cetuximab PET scan, which showed no uptake
after one cycle of cetuximab (E.J. van Helden,
unpublished data). Second, stable disease could also
be a result of tumor heterogeneity, whereby only a
small fraction of tumor cells harbor KRAS mutations
and the majority are RAS wild-type (Benvenuti et al.,
2007; Karapetis et al., 2008). A final possible expla-
nation is that there were other reasons for an indo-
lent disease course regardless of treatment with
cetuximab.
Given that the KRAS and BRAF mutations detected
in ctDNA indeed conferring resistance to cetuximab,
we were interested to see whether these mutations
would be present throughout disease course and
whether new mutations would appear. When we ana-
lyzed the mutation status in ctDNA at progression, we
found that in patients who had shown initial treatment
benefit, 12/17 (71%) patients had new RAS and/or
BRAF mutations that were not detected at the start of
the study. The fact that nine of these patients (9/12,
75%) had multiple mutations in these genes and
codons suggests that the resistance to anti-EGFR
treatment is caused by the emergence of various clones
harboring different mutations. Our finding of a rela-
tively high number of patients treated with cetuximab
who harbor RAS mutations at disease progression is
in line with that of a previous study (Diaz et al., 2012;
Misale et al., 2012; Siravegna et al., 2015; Van
Emburgh et al., 2016). They reported RAS mutations
in tumor tissue and ctDNA in 74% of patients who
were mainly being treated with a combination of
cetuximab and irinotecan. These mutations are most
likely acquired by the tumor as a means of escape
from the continuous pressure exerted by anti-EGFR
MoAbs. But it is also possible that the mutations are
due to tumor heterogeneity resulting in the selection
and outgrowth of multiple-resistant RAS/BRAF-mu-
tated subclones, which are below the limit of detection
at baseline.
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Interestingly, at progression 8/17 patients (47%)
with initial benefit had gained an EGFR mutation in
ctDNA, and for six of these patients, these mutations
were also polyclonal. EGFR mutations in codon 465
were detected in seven patients, in codon 464 in six
patients, and in codon 492 in two patients. All of these
EGFR mutations are located in domain III of the
receptor and alter the epitope to which cetuximab
binds, thereby inhibiting binding of cetuximab to
EGFR (Arena et al., 2015, 2016; Bertotti et al., 2015;
Esposito et al., 2013; Sickmier et al., 2016; Voigt
et al., 2012). Esposito et al. (2013) have suggested that
these mutations only occur after treatment with cetux-
imab, as evidenced by their study of 505 patients, in
which mutations in tumor tissue were detected after
anti-EGFR therapy but not before. In our cohort,
these EGFR mutations were also exclusively found at
progression, rendering this mutation unsuitable for
patient selection. It has been proposed that while these
EGFR mutations occur after cetuximab therapy, they
do not emerge after panitumumab therapy, leaving
these tumor cells sensitive to panitumumab therapy
(Montagut et al., 2012). However, given our observa-
tion that these mutations are almost always accompa-
nied by other RAS or BRAF mutations, a treatment
switch to panitumumab in EGFR-mutated patients will
probably not result in treatment benefit. Also, given
the heterogeneity and convergence of the mutational
pattern at progression, targeted blockage of the EGFR
pathway will likely be difficult.
Finally, it is worth pointing out our finding of a cor-
relation between the number of mutated molecules per
mL plasma and the MATV measured by [18F]FDG
PET before treatment. A similar correlation has been
described previously in patients with non-small-cell
lung cancer starting with erlotinib in a palliative set-
ting (Winther-Larsen et al., 2017). To our knowledge,
our study is the first to show a similar correlation
between the number of mutated molecules and MATV
measured by [18F]FDG PET in patients with mCRC.
Our study thereby supports the hypothesis that the
total number of mutated molecules per mL plasma
could serve as a surrogate for tumor load, which has
also been described using CT to estimate tumor bur-
den (Diehl et al., 2008). Important to note is that both
techniques, [18F]FDG PET and ctDNA, are sensitive-
limited technologies hampering both techniques to
detect low tumor burden. Next to the correlation
between mutant molecules and MATV, we also found
a correlation between the cfDNA concentration and
MATV. It should be noted that the correlation
between cfDNA and MATV might be less tumor
specific, since cfDNA is composed of a small fraction
of tumor DNA, while the majority is derived from
normal apoptotic tissue and hematological cells (Elshi-
mali et al., 2013; Jahr et al., 2001).
There are several limitations of our study including
the small sample size. Second, in our study, tumor tis-
sues were sequenced with panels used in daily routine
practice. Therefore, comparative analyses of ctDNA
and tumor tissue were hampered by the use of differ-
ent techniques.
5. Conclusions
NGS of ctDNA in patients with tissue-tested RAS
wild-type mCRC – tested as part of routine clinical
work-up – can identify additional RAS mutation car-
riers. The majority of patients with initial clinical
benefit from cetuximab therapy gain mutations in
genes such as RAS, BRAF, and EGFR, frequently
occurring in multiple clones within individual
patients. Hence, ctDNA analysis is a promising tool
to optimize patient selection for anti-EGFR mono-
clonal antibodies and a minimally invasive method to
gain more insight in mechanisms accounting for resis-
tance.
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Fig. S1. cfDNA concentration measured in matched
baseline, 2 weeks and PD samples. Each line indicates
one patient. cfDNA concentrations were available for
9 matched baseline and 2 week samples, and for 6 PD
samples.* Related samples Wilcoxon signed-rank test.
Fig. S2. Patient 23 having a polyclonal KRAS muta-
tion present at baseline, a marked decrease in the
TP53 p.R158H mutant allele frequency (MAF) after
two weeks of treatment and an increase of the AMF
at disease progression accompanied by emergence of
four additional KRAS and two NRAS mutation.
Fig. S3. Scatter plot of the concentration cfDNA (in
ng per mL plasma) (A) and the number of mutant
molecules per mL plasma (B) versus the sum of
metabolically active tumor volume (MATV) on [18F]
FDG PET scan per patient.
Table S1. cfDNA concentrations and ng DNA input
for targeted NGS.
Table S2. Sequencing failures.
Table S3. Double biopsies.
Table S4. Overview of all available mutation data.
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